These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 12237622)

  • 1. Antitumor effects of the cytotoxic luteinizing hormone-releasing hormone analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice.
    Gründker C; Völker P; Griesinger F; Ramaswamy A; Nagy A; Schally AV; Emons G
    Am J Obstet Gynecol; 2002 Sep; 187(3):528-37. PubMed ID: 12237622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone.
    Miyazaki M; Nagy A; Schally AV; Lamharzi N; Halmos G; Szepeshazi K; Groot K; Armatis P
    J Natl Cancer Inst; 1997 Dec; 89(23):1803-9. PubMed ID: 9392622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits growth of OV-1063 human epithelial ovarian cancers in nude mice.
    Miyazaki M; Schally AV; Nagy A; Lamharzi N; Halmos G; Szepeshazi K; Armatis P
    Am J Obstet Gynecol; 1999 May; 180(5):1095-103. PubMed ID: 10329861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Luteinizing hormone-releasing hormone receptor-targeted chemotherapy using AN-152.
    Emons G; Sindermann H; Engel J; Schally AV; Gründker C
    Neuroendocrinology; 2009; 90(1):15-8. PubMed ID: 19521066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective treatment of experimental human endometrial cancers with targeted cytotoxic luteinizing hormone-releasing hormone analogues AN-152 and AN-207.
    Engel JB; Keller G; Schally AV; Nagy A; Chism DD; Halmos G
    Fertil Steril; 2005 Apr; 83 Suppl 1():1125-33. PubMed ID: 15831285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective treatment of experimental ES-2 human ovarian cancers with a cytotoxic analog of luteinizing hormone-releasing hormone AN-207.
    Arencibia JM; Bajo AM; Schally AV; Krupa M; Chatzistamou I; Nagy A
    Anticancer Drugs; 2002 Oct; 13(9):949-56. PubMed ID: 12394258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.
    Engel J; Emons G; Pinski J; Schally AV
    Expert Opin Investig Drugs; 2012 Jun; 21(6):891-9. PubMed ID: 22577891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Administration of a targeted cytotoxic analog of luteinizing hormone-releasing hormone inhibits growth of estrogen-independent MDA-MB-231 human breast cancers in nude mice.
    Kahán Z; Nagy A; Schally AV; Halmos G; Arencibia JM; Groot K
    Breast Cancer Res Treat; 2000 Feb; 59(3):255-62. PubMed ID: 10832595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting of doxorubicin to ES-2 human ovarian cancers in nude mice by linking to an analog of luteinizing hormone-releasing hormone improves its effectiveness.
    Arencibia JM; Schally AV; Krupa M; Bajo AM; Nagy A; Szepeshazi K; Plonowski A
    Int J Oncol; 2001 Sep; 19(3):571-7. PubMed ID: 11494038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers.
    Nagy A; Schally AV
    Biol Reprod; 2005 Nov; 73(5):851-9. PubMed ID: 16033997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Internalization of cytotoxic analog AN-152 of luteinizing hormone-releasing hormone induces apoptosis in human endometrial and ovarian cancer cell lines independent of multidrug resistance-1 (MDR-1) system.
    Günthert AR; Gründker C; Bongertz T; Schlott T; Nagy A; Schally AV; Emons G
    Am J Obstet Gynecol; 2004 Oct; 191(4):1164-72. PubMed ID: 15507937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Receptor mediated antiproliferative effects of the cytotoxic LHRH agonist AN-152 in human ovarian and endometrial cancer cell lines.
    Westphalen S; Kotulla G; Kaiser F; Krauss W; Werning G; Elsasser HP; Nagy A; Schulz KD; Grundker C; Schally AV; Emons G
    Int J Oncol; 2000 Nov; 17(5):1063-9. PubMed ID: 11029513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complete regression of MX-1 human breast carcinoma xenografts after targeted chemotherapy with a cytotoxic analog of luteinizing hormone-releasing hormone, AN-207.
    Kahán Z; Nagy A; Schally AV; Halmos G; Arencibia JM; Groot K
    Cancer; 1999 Jun; 85(12):2608-15. PubMed ID: 10375109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
    Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
    Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted chemotherapy of endometrial, ovarian and breast cancers with cytotoxic analogs of luteinizing hormone-releasing hormone (LHRH).
    Engel JB; Schally AV; Buchholz S; Seitz S; Emons G; Ortmann O
    Arch Gynecol Obstet; 2012 Aug; 286(2):437-42. PubMed ID: 22555802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207.
    Stangelberger A; Schally AV; Nagy A; Szepeshazi K; Kanashiro CA; Halmos G
    Prostate; 2006 Feb; 66(2):200-10. PubMed ID: 16173040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers.
    Bajo AM; Schally AV; Halmos G; Nagy A
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3742-8. PubMed ID: 14506166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of in vivo proliferation of MDA-PCa-2b human prostate cancer by a targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207.
    Plonowski A; Schally AV; Nagy A; Groot K; Krupa M; Navone NM; Logothetis C
    Cancer Lett; 2002 Feb; 176(1):57-63. PubMed ID: 11790454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effective treatment of metastatic MDA-MB-435 human estrogen-independent breast carcinomas with a targeted cytotoxic analogue of luteinizing hormone-releasing hormone AN-207.
    Chatzistamou L; Schally AV; Nagy A; Armatis P; Szepeshazi K; Halmos G
    Clin Cancer Res; 2000 Oct; 6(10):4158-65. PubMed ID: 11051271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor effects of cecropin B-LHRH' on drug-resistant ovarian and endometrial cancer cells.
    Li X; Shen B; Chen Q; Zhang X; Ye Y; Wang F; Zhang X
    BMC Cancer; 2016 Mar; 16():251. PubMed ID: 27021903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.